Vancomycin inhalation powder (AeroVanc™) is an inhaled dry powder version of the antibiotic vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) airway infection in people with CF.
Results from a U.S. multicenter Phase 2 trial showed that study participants who received AeroVanc™ experienced a significant reduction in MRSA density in their sputum compared with those given a placebo.
This program is sponsored by Savara Pharmaceuticals and partially funded by Cystic Fibrosis Foundation Therapeutics. It is being conducted within CFFT's Therapeutics Development Network.
Contact us about Vancomycin Inhalation Powder (AeroVanc™) >